AmerisourceBergen Finalizes Billion-dollar Deal for PharmaLex

Drug wholesaler AmerisourceBergen Corp. has officially acquired PharmaLex, a healthcare and life sciences consulting and outsourcing service provider. The deal—definitively agreed upon in September and now valued at approximately $1.35 billion—not only expands ABCs geographic reach, but enhances the company’s portfolio of solutions to support partners across the pharmaceutical development and commercialization journey.

Headquartered in Germany, PharmaLex has global reach, including a footprint in Europe and the US, and a presence in other parts of the world. The provider’s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance services are expected to complement the drug wholesaler’s commercialization solutions.

“The opportunity to join AmerisourceBergen is a positive step forward for PharmaLex and extends the value and support we can provide our partners as they look to bring products to market,” says Thomas Dobmeyer, CEO and managing partner, PharmaLex. “Our clients will now have access to a more robust and expansive suite of global solutions and services that can be tailored to meet their specific needs at any point in the product lifecycle—from taking a product through clinical trials to pharmaceutical distribution and accelerating patient access to prescribed medication.”